

24 DEC 2009

Dr H Markus
ST GEORGE'S UNIVERSITY OF LONDON
CRANMER TERRACE
LONDON
SW17 0RE
UNITED KINGDOM

23/12/2009

Dear Dr H Markus

THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATIONS 2004 S.I. 2004/1031

Our Reference: 16745/0205/001-0016
Eudract Number: 2006-002827-18
Product: Aspirin
Protocol number: RBF0032
Substantial Amendment Code Number: 04/Q0803/215, Substantial amendment No. 15, 24/09/09

NOTICE OF ACCEPTANCE OF AMENDMENT

I am writing to inform you that the Licensing Authority accepts the proposed amendment to your clinical trial authorisation (CTA), received on 23/11/2009.

This amendment may therefore be made.

You are reminded that where it is appropriate, the Ethics Committee should also be notified of amendments.

Yours sincerely,

**Clinical Trials Unit
MHRA**

? Yours